United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects [Seeking Alpha]
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Seeking Alpha
UTHR's treatments for cardiovascular disorders include PAH, PH-ILD, and pediatric oncology drugs. The company's revenue relies heavily on Tyvaso, which faces legal challenges that potentially affect future growth. Such legal challenges over Tyvaso's patent pose significant risks to the company's valuation and market exclusivity. Despite risks, United Therapeutics has a strong financial position, with a comprehensive product portfolio and promising clinical trials. On balance, I lean neutral on UTHR until legal headwinds dissipate, so I rate it a "hold" for now. United Therapeutics Corporation ( NASDAQ: UTHR ) is a biotechnology and pharmaceutical company specializing in cardiovascular disorder treatments such as Pulmonary Arterial Hypertension [PAH], Pulmonary Hypertension associated with Interstitial Lung Disease [PH-ILD], and pediatric oncology drugs. Its research pipeline advances its lung disorders platforms, develops novel biologics to treat sepsis, and generates variou
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- United Therapeutics Co. (NASDAQ: UTHR) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $218.00 to $240.00. They now have a "neutral" rating on the stock.MarketBeat
- United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Corporation (NASDAQ:UTHR) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- United Therapeutics Co. (NASDAQ: UTHR) had its price target raised by analysts at Oppenheimer Holdings Inc. from $375.00 to $400.00. They now have an "outperform" rating on the stock.MarketBeat
- United Therapeutics Co. (NASDAQ: UTHR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $300.00 price target on the stock.MarketBeat
UTHR
Earnings
- 5/1/24 - Beat
UTHR
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 144
- 5/3/24 - Form 144
- UTHR's page on the SEC website